Eiry Roberts - Nov 8, 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Medical Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Nov 8, 2024
Transactions value $
$599,873
Form type
4
Date filed
11/12/2024, 05:58 PM
Previous filing
Jun 7, 2024
Next filing
Dec 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $400K +5.14K +21.67% $77.81 28.9K Nov 8, 2024 Direct F1
transaction NBIX Common Stock Options Exercise $99.9K +1.23K +4.27% $81.05 30.1K Nov 8, 2024 Direct F1
transaction NBIX Common Stock Options Exercise $99.9K +971 +3.23% $102.90 31.1K Nov 8, 2024 Direct F1
transaction NBIX Common Stock Options Exercise $79.00 +1 +0% $79.02 31.1K Nov 8, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Incentive Stock Option Options Exercise $0 -5.14K -100% $0.00 0 Nov 8, 2024 Common Stock 5.14K $77.81 Direct F3
transaction NBIX Incentive Stock Option Options Exercise $0 -1.23K -100% $0.00 0 Nov 8, 2024 Common Stock 1.23K $81.05 Direct F4
transaction NBIX Incentive Stock Option Options Exercise $0 -971 -100% $0.00 0 Nov 8, 2024 Common Stock 971 $102.90 Direct F5
transaction NBIX Incentive Stock Option Options Exercise $0 -1 -0.08% $0.00 1.27K Nov 8, 2024 Common Stock 1 $79.02 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
F2 29,876 of the outstanding shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
F3 Represents option of which 1/4th of the shares underlying the option became vested and exercisable on January 8, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F4 Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F5 Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and excercisable each month thereafter.
F6 Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.